Effects of a dual inhibitor of angiotensin converting enzyme and neutral endopeptidase, MDL 100,240, on endocrine and renal functions in healthy volunteers

• Published in: Journal of hypertension Vol. 17; no. 3; p. 427
• Main Authors: Rousso, P, Buclin, T, Nussberger, J, Décosterd, L A, La Roche, S D, Brunner-Ferber, F, Brunner, H R, Biollaz, J
• Format: Journal Article
• Language: English
• Published: England 01.03.1999
• Subjects: Adult; Angiotensin II - blood; Angiotensin-Converting Enzyme Inhibitors - pharmacology; Atrial Natriuretic Factor - blood; Atrial Natriuretic Factor - urine; Benzazepines - pharmacology; Blood Pressure - drug effects; Cross-Over Studies; Cyclic GMP - urine; Diet, Sodium-Restricted; Endocrine System - drug effects; Follow-Up Studies; Humans; Infusions, Intravenous; Kidney - drug effects; Male; Neprilysin - antagonists & inhibitors; Neprilysin - blood; Peptidyl-Dipeptidase A - blood; Peptidyl-Dipeptidase A - drug effects; Posture; Pyridines - pharmacology; Reference Values; Renal Plasma Flow, Effective - drug effects; Safety; Stereoisomerism

To investigate the endocrine and renal effects of the dual inhibitor of angiotensin converting enzyme and neutral endopeptidase, MDL 100,240. A randomized, placebo-controlled, crossover study was performed in 12 healthy volunteers. MDL 100,240 was administered intravenously over 20 min at single dos...